State of Wisconsin Investment Board’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $14.7M | Sell |
87,254
-9,007
| -9% | -$1.34M | 0.03% | 495 |
|
|
2026
Q1 | $12.7M | Buy |
96,261
+1,734
| +2% | +$230K | 0.03% | 542 |
|
|
2025
Q4 | $13.4M | Sell |
94,527
-4,264
| -4% | -$618K | 0.03% | 533 |
|
|
2025
Q3 | $13.9M | Sell |
98,791
-8,119
| -8% | -$1.1M | 0.03% | 485 |
|
|
2025
Q2 | $13.4M | Sell |
106,910
-4,475
| -4% | -$513K | 0.03% | 500 |
|
|
2025
Q1 | $12.3M | Buy |
111,385
+25,236
| +29% | +$3.2M | 0.03% | 521 |
|
|
2024
Q4 | $11.8M | Sell |
86,149
-3,615
| -4% | -$447K | 0.03% | 557 |
|
|
2024
Q3 | $10.3M | Buy |
89,764
+14,556
| +19% | +$2M | 0.03% | 630 |
|
|
2024
Q2 | $10.4M | Buy |
75,208
+2,939
| +4% | +$403K | 0.03% | 567 |
|
|
2024
Q1 | $9.97M | Buy |
72,269
+15,971
| +28% | +$2.18M | 0.03% | 624 |
|
|
2023
Q4 | $7.42M | Sell |
56,298
-519
| -0.9% | -$59.7K | 0.02% | 788 |
|
|
2023
Q3 | $6.39M | Sell |
56,817
-4,463
| -7% | -$470K | 0.02% | 798 |
|
|
2023
Q2 | $5.78M | Sell |
61,280
-174
| -0.3% | -$17K | 0.02% | 888 |
|
|
2023
Q1 | $6.22M | Sell |
61,454
-2,741
| -4% | -$285K | 0.02% | 841 |
|
|
2022
Q4 | $7.67M | Sell |
64,195
-5,978
| -9% | -$700K | 0.02% | 707 |
|
|
2022
Q3 | $7.45M | Sell |
70,173
-12,297
| -15% | -$1.25M | 0.02% | 709 |
|
|
2022
Q2 | $8.04M | Sell |
82,470
-5,801
| -7% | -$535K | 0.02% | 751 |
|
|
2022
Q1 | $8.28M | Sell |
88,271
-166,073
| -65% | -$14.1M | 0.02% | 894 |
|
|
2021
Q4 | $21.7M | Buy |
254,344
+54,546
| +27% | +$5.02M | 0.04% | 441 |
|
|
2021
Q3 | $19.2M | Buy |
199,798
+86,976
| +77% | +$8.22M | 0.04% | 483 |
|
|
2021
Q2 | $11M | Buy |
112,822
+61,370
| +119% | +$5.88M | 0.02% | 716 |
|
|
2021
Q1 | $5M | Sell |
51,452
-12,241
| -19% | -$1.28M | 0.01% | 1019 |
|
|
2020
Q4 | $6.11M | Sell |
63,693
-4,110
| -6% | -$397K | 0.01% | 923 |
|
|
2020
Q3 | $6.52M | Buy |
67,803
+430
| +0.6% | +$49.7K | 0.02% | 834 |
|
|
2020
Q2 | $8.22M | Sell |
67,373
-340
| -0.5% | -$37.6K | 0.02% | 679 |
|
|
2020
Q1 | $5.86M | Sell |
67,713
-37,125
| -35% | -$3.63M | 0.02% | 720 |
|
|
2019
Q4 | $11.3M | Buy |
104,838
+92,035
| +719% | +$9.64M | 0.03% | 618 |
|
|
2019
Q3 | $1.15M | Sell |
12,803
-74
| -0.6% | -$6.91K | ﹤0.01% | 1108 |
|
|
2019
Q2 | $1.09M | Sell |
12,877
-3,985
| -24% | -$327K | ﹤0.01% | 1117 |
|
|
2019
Q1 | $1.49M | Sell |
16,862
-240
| -1% | -$20.1K | ﹤0.01% | 1058 |
|
|
2018
Q4 | $1.22M | Hold |
17,102
| – | – | ﹤0.01% | 1078 |
|
|
2018
Q3 | $2.1M | Sell |
17,102
-370
| -2% | -$42K | 0.01% | 1034 |
|
|
2018
Q2 | $1.72M | Sell |
17,472
-293
| -2% | -$26.2K | ﹤0.01% | 1018 |
|
|
2018
Q1 | $1.47M | Sell |
17,765
-166
| -0.9% | -$14K | ﹤0.01% | 1025 |
|
|
2017
Q4 | $1.39M | Buy |
17,931
+147
| +0.8% | +$10K | ﹤0.01% | 1031 |
|
|
2017
Q3 | $1.09M | Buy |
17,784
+372
| +2% | +$19.6K | ﹤0.01% | 1072 |
|
|
2017
Q2 | $801K | Sell |
17,412
-2,080
| -11% | -$101K | ﹤0.01% | 1139 |
|
|
2017
Q1 | $844K | Sell |
19,492
-29,735
| -60% | -$1.27M | ﹤0.01% | 1068 |
|
|
2016
Q4 | $1.91M | Sell |
49,227
-8,073
| -14% | -$365K | 0.01% | 1056 |
|
|
2016
Q3 | $2.9M | Sell |
57,300
-1,000
| -2% | -$49.8K | 0.01% | 971 |
|
|
2016
Q2 | $2.65M | Buy |
+58,300
| New | +$2.68M | 0.01% | 987 |
|
Other funds holding NBIX
State of Wisconsin Investment Board's NBIX Position: Q2 2026 in Review
State of Wisconsin Investment Board reduced its Neurocrine Biosciences (NBIX) stake by 9.4% in Q2 2026, selling an estimated $1.34M and leaving 87,254 shares worth $14.7M. The position accounts for 0.03% of the portfolio, ranked #495.
State of Wisconsin Investment Board first reported a position in NBIX in Q2 2016 and has held it in 41 quarters since. The position peaked at $21.7M in Q4 2021. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- State of Wisconsin Investment Board held 87,254 shares of Neurocrine Biosciences worth $14.7M as of Q2 2026.
- State of Wisconsin Investment Board sold 9,007 Neurocrine Biosciences shares in Q2 2026, an estimated $1.34M.
- Neurocrine Biosciences made up 0.03% of State of Wisconsin Investment Board's portfolio in Q2 2026, its #495 holding.
- State of Wisconsin Investment Board first reported a position in Neurocrine Biosciences in Q2 2016 and has held it in 41 quarters since.
- State of Wisconsin Investment Board's Neurocrine Biosciences position peaked at $21.7M in Q4 2021.
- 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on State of Wisconsin Investment Board's 13F filing for Q2 2026, filed 14 Aug 2026.